A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and
pharmacokinetics (PK) of single intrathecal (IT) doses of ALN-APP in adult patients with
early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose.
Maximum treatment for Part B: 12 months.